Lung Cancer
NSCLC - Trending Clinical Trials by Stage and Product
- EGFRmut
- EGFRmut exon 20
- ALK+
- Immunotherapy Trials
- ADC/Bispecifics
- KRASG12C
- HER2
- LS-SCLC
- ES-SCLC
| Stage / Product | Tagrisso | Tagrisso plus chemo | Rybrevant + Lazcluze | Rybrevant + chemo | Ivonescimab plus chemo | Datroway |
|---|---|---|---|---|---|---|
| Stage IV 2nd Line |
HARMONi
Sponsor: Summit Therapeutics
WCLC25 Presentation
|
|||||
| Stage IV First Line | ||||||
| Stage III Unresectable | ||||||
| Stages IA- IIIB |
| Stage / Product | Rybrevant + chemo |
|---|---|
| Stage IV Second Line |
PAPILLON
Sponsor Johnson & Johnson
FDA Approved
|
| Stage IV First Line | |
| Resectable - Adjuvant |
| Stage/Product | Alecensaa | Ensacove | Lorbrena |
|---|---|---|---|
| Locally Advanced or Metastatic |
EXALT-3
Sponsor: Xcovery
FDA Approved
|
CROWN
Sponsor: Pfizer
FDA Approved
|
|
| Resectable Adjuvant |
ALINA
Sponsor: Genentech
FDA Approved
|
| Stage / Product | Keytruda + chemo | Keytruda | Opdivo + chemo | Imfinzi + chemo |
|---|---|---|---|---|
| STAGE IV | ||||
| Stage III Unresectable | ||||
| Resectable: Adjuvant | ||||
| Resectable: Perioperative |
CheckMate 77T
Sponsor Bristol Myers Squibb
FDA Approved
|
AEGEAN
Sponsor AstraZeneca
FDA Approved
|
||
| Resectable: Neoadjuvant |
KEYNOTE-671
Sponsor Merck
Pending FDA Review
|
CheckMate 816
Sponsor Bristol Myers Squibb
FDA Approved
|
| Trodelvy | Ivonescimab | |
|---|---|---|
| Adv/Metastatic 2L |
EVOKE-01
Gilead
presented at ASCO24
|
|
| Adv/Metastatic 1L |
HARMON-i
Summit Therapeutics
submitted to FDA, Presentation at World Lung 2025
|
| Stage/Product | Krazati |
|---|---|
| Stage IV Second Line | |
| Stage IV First Line |
KRYSTAL-12
Sponsor Mirati
FDA Confirmatory trial
|
| Stage/Product | Zongertinib | Enhertu |
|---|---|---|
| Stage IV Second Line |
BEAMION-Lung1
Sponsor Boehringer Ingelheim
FDA Approved
|
DESTINY-Lung02
Sponsor Daiichi Sankyo/AstraZeneca
FDA Approved
|
| Stage IV: First Line |
| Stage / Product | Imfinzi + tremelimumab or placebo |
|---|---|
| LS - SCLC 1L |
ADRIATIC
Sponsor AstraZeneca
FDA Approved
|
| Stage/Product | Imdelltra | Zepzelca |
|---|---|---|
| ES-SCLC relapsed/refractory |
DeLLPhi 304
Sponsor Amgen
FDA Approved
|
|
| ES-SCLC Maintenance |
IMForte
Sponsor Jazz Pharmaceuticals
presented at ASCO25
|
SCLC - Trending Clinical Trials by Stage and Product
- ES-SCLC
- LS-SCLC
| Stage/Product | Imdelltra | Zepzelca |
|---|---|---|
| ES-SCLC relapsed/refractory |
DeLLPhi 304
Sponsor Amgen
FDA Approved
|
|
| ES-SCLC Maintenance |
IMForte
Sponsor Jazz Pharmaceuticals
FDA Approved
|
| Stage / Product | Imfinzi + tremelimumab or placebo |
|---|---|
| LS - SCLC 1L |
ADRIATIC
Sponsor AstraZeneca
FDA Approved
|
